 This scoping review is the first to examine the use of decision impact studies, DIS, in genomic medicine and cancer care. It found that these studies are used to evaluate the impact of a genomic test on decision making and report on a variety of clinical utility outcomes such as provider slash team decision making, provider confidence, patient psychological impacts, and costing or savings impacts. This review suggests that DIS may provide evidence of clinical utility and impact clinical practice and reimbursement decision making in cancer care. This article was authored by Jillian Parker, Sarah Hunter, Samar Ghazi, and others.